RxDoctor Payments Data

Sheema Imran, MD

Geriatric Psychiatry · Perth Amboy, NJNPI 1427462019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 25.9% of the total. Reporting peaked in 2023 at $339 and has fallen 69.1% since, to $105 in 2025.

$853in general payments, 2019–2025

Across 52 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$221
  • Alkermes, Inc.$216
  • Indivior Inc.$127
  • Otsuka America Pharmaceutical, Inc.$79
  • Johnson & Johnson$77
  • Neurocrine Biosciences, Inc.$46
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$853100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$853 in reported general payments places this provider in the 80th percentile of 26 geriatric psychiatry providers in New Jersey.

See all geriatric psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$119,810
Medicare patients
156
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayosPrednisone14$96,305
Invega SustennaPaliperidone Palmitate13$50,774
Lurasidone Hcl17$7,226
Olanzapine OdtOlanzapine20$1,642
Risperidone OdtRisperidone12$1,452
Divalproex Sodium ErDivalproex Sodium13$675
Gabapentin29$457
Atorvastatin Calcium68$397
Olanzapine25$393
Duloxetine Hcl14$386
Venlafaxine Hcl ErVenlafaxine Hcl26$300
Mirtazapine18$280
Pantoprazole Sodium36$271
Ropinirole Hcl12$210
Quetiapine Fumarate16$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$77$50,77413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 26 geriatric psychiatry providers in New Jersey.

Other geriatric psychiatry in Perth Amboy

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →